# ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)

> **NCT00090363** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 447 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** ZD4054 15 mg
- **DRUG:** Placebo
- **DRUG:** ZD4054 10 mg

## Key facts

- **NCT ID:** NCT00090363
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2008-12
- **Final completion:** 2011-08
- **Target enrollment:** 447 (ACTUAL)
- **Last updated:** 2013-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090363, "ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00090363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*